Treatment Strategies for Therapy-Related and De Novo AML
February 11, 2026 • AML Clinical Content Hub
In this Oncology Brothers podcast episode, Naval Daver, MD, MD Anderson Cancer Center, Houston, Texas, discusses treatment strategies for both therapy‑related and de novo acute myeloid leukemia (AML), focusing on cases where traditional induction chemotherapy may not be feasible. He reviews the differences in prognosis, compares induction options like CPX‑351 versus the standard 7+3 regimen, and highlights the use of hypomethylating agents plus venetoclax for older or unfit patients, especially those with specific mutations like NPM1, while also addressing practical considerations for inpatient and outpatient care.
